Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2021-10-07 20:41:52 UTC |
---|
NP-MRD ID | NP0000605 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | L-Dopa |
---|
Description | L-DOPA, also known as levodopa or 3,4-dihydroxyphenylalanine is an alpha amino acid. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon). L-DOPA is found naturally in both animals and plants. It is made via biosynthesis from the amino acid L-tyrosine by the enzyme tyrosine hydroxylase.. L-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. The Swedish scientist Arvid Carlsson first showed in the 1950s that administering L-DOPA to animals with drug-induced (reserpine) Parkinsonian symptoms caused a reduction in the intensity of the animals' symptoms. Unlike dopamine itself, L-DOPA can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. In particular, it is metabolized to dopamine by aromatic L-amino acid decarboxylase. Pyridoxal phosphate (vitamin B6) is a required cofactor for this decarboxylation, and may be administered along with levodopa, usually as pyridoxine. As a result, L-DOPA is a drug that is now used for the treatment of Parkinsonian disorders and DOPA-Responsive Dystonia. It is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. It is standard clinical practice in treating Parkinsonism to co-administer a peripheral DOPA decarboxylase inhibitor - carbidopa or benserazide - and often a catechol-O-methyl transferase (COMT) inhibitor, to prevent synthesis of dopamine in peripheral tissue. Side effects of L-DOPA treatment may include: Hypertension, arrhythmias, nausea, gastrointestinal bleeding, disturbed respiration, hair loss, disorientation and confusion. L-DOPA can act as an L-tyrosine mimetic and be incorporated into proteins by mammalian cells in place of L-tyrosine, generating protease-resistant and aggregate-prone proteins in vitro and may contribute to neurotoxicity with chronic L-DOPA administration. L-phenylalanine, L-tyrosine, and L-DOPA are all precursors to the biological pigment melanin. The enzyme tyrosinase catalyzes the oxidation of L-DOPA to the reactive intermediate dopaquinone, which reacts further, eventually leading to melanin oligomers. |
---|
Structure | N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine | ChEBI | (-)-Dopa | ChEBI | 3,4-Dihydroxy-L-phenylalanine | ChEBI | 3,4-DIHYDROXYPHENYLALANINE | ChEBI | 3-Hydroxy-L-tyrosine | ChEBI | beta-(3,4-Dihydroxyphenyl)-L-alanine | ChEBI | beta-(3,4-Dihydroxyphenyl)alanine | ChEBI | Dihydroxy-L-phenylalanine | ChEBI | Dopar | ChEBI | L-beta-(3,4-Dihydroxyphenyl)alanine | ChEBI | Levodopa | ChEBI | Levodopum | ChEBI | b-(3,4-Dihydroxyphenyl)-L-alanine | Generator | Β-(3,4-dihydroxyphenyl)-L-alanine | Generator | b-(3,4-Dihydroxyphenyl)alanine | Generator | Β-(3,4-dihydroxyphenyl)alanine | Generator | L-b-(3,4-Dihydroxyphenyl)alanine | Generator | L-Β-(3,4-dihydroxyphenyl)alanine | Generator | (2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoate | HMDB | (2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid | HMDB | 3,4-Dihydroxyphenyl-L-alanine | HMDB | 3-(3,4-Dihydroxyphenyl)-L-alanine | HMDB | b-(3,4-Dihydroxyphenyl)-a-L-alanine | HMDB | Bendopa | HMDB | beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine | HMDB | Cidandopa | HMDB | Dihydroxyphenylalanine | HMDB | Dopaflex | HMDB | Dopaidan | HMDB | Dopal | HMDB | Dopalina | HMDB | Doparkine | HMDB | Doparl | HMDB | Dopasol | HMDB | Dopaston | HMDB | Dopastone | HMDB | Dopastral | HMDB | Dopicar | HMDB | Doprin | HMDB | Eldopal | HMDB | Eldopar | HMDB | Eldopatec | HMDB | Eurodopa | HMDB | Helfo-dopa | HMDB | Insulamina | HMDB | L-(-)-Dopa | HMDB | L-3-(3,4-Dihydroxyphenyl)-alanine | HMDB | L-4-5-Dihydroxyphenylalanine | HMDB | L-b-(3,4-Dihydroxyphenyl)-a-alanine | HMDB | L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine | HMDB | L-Dihydroxyphenylalanine | HMDB | Laradopa | HMDB | Larodopa | HMDB | Ledopa | HMDB | Levedopa | HMDB | Levopa | HMDB | Maipedopa | HMDB | Parda | HMDB | Pardopa | HMDB | Prodopa | HMDB | Syndopa | HMDB | Veldopa | HMDB | Weldopa | HMDB | 3 Hydroxy L tyrosine | HMDB | Roche brand OF levodopa | HMDB | L 3,4 Dihydroxyphenylalanine | HMDB | L-3,4-Dihydroxyphenylalanine | HMDB | Medphano brand OF levodopa | HMDB | L Dopa | HMDB | Roberts brand OF levodopa | HMDB |
|
---|
Chemical Formula | C9H11NO4 |
---|
Average Mass | 197.1879 Da |
---|
Monoisotopic Mass | 197.06881 Da |
---|
IUPAC Name | (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
---|
Traditional Name | levodopa |
---|
CAS Registry Number | 59-92-7 |
---|
SMILES | N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O |
---|
InChI Identifier | InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 |
---|
InChI Key | WTDRDQBEARUVNC-LURJTMIESA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as tyrosine and derivatives. Tyrosine and derivatives are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Tyrosine and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Tyrosine or derivatives
- Phenylalanine or derivatives
- 3-phenylpropanoic-acid
- Alpha-amino acid
- Amphetamine or derivatives
- L-alpha-amino acid
- Catechol
- 1-hydroxy-4-unsubstituted benzenoid
- Aralkylamine
- 1-hydroxy-2-unsubstituted benzenoid
- Phenol
- Monocyclic benzene moiety
- Benzenoid
- Amino acid
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Primary amine
- Primary aliphatic amine
- Organic nitrogen compound
- Organic oxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Organopnictogen compound
- Amine
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | 285 °C | Not Available | Boiling Point | 447.00 to 449.00 °C. @ 760.00 mm Hg | The Good Scents Company Information System | Water Solubility | 5 mg/mL | Not Available | LogP | -2.39 | Sangster, J. (1993). LOGKOW- a Databank of Evaluated Octanol-Water Partition Coefficients. Sangster Research Laboratories, Montreal. |
|
---|
Predicted Properties | |
---|
General References | - Goldstein DS, Eisenhofer G, Kopin IJ: Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther. 2003 Jun;305(3):800-11. Epub 2003 Mar 20. [PubMed:12649306 ]
- Cools R: Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006;30(1):1-23. Epub 2005 Jun 1. [PubMed:15935475 ]
- de Jong AP, Kok RM, Cramers CA, Wadman SK, Haan E: A new method for the determination of L-dopa and 3-O-methyldopa in plasma and cerebrospinal fluid using gas chromatography and electron capture negative ion mass spectrometry. Clin Chim Acta. 1988 Jan 15;171(1):49-61. [PubMed:3127089 ]
- Dutton J, Copeland LG, Playfer JR, Roberts NB: Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor. Clin Chem. 1993 Apr;39(4):629-34. [PubMed:8472357 ]
- Mercuri NB, Bernardi G: The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci. 2005 Jul;26(7):341-4. [PubMed:15936832 ]
- Goldstein DS, Hahn SH, Holmes C, Tifft C, Harvey-White J, Milstien S, Kaufman S: Monoaminergic effects of folinic acid, L-DOPA, and 5-hydroxytryptophan in dihydropteridine reductase deficiency. J Neurochem. 1995 Jun;64(6):2810-3. [PubMed:7760062 ]
- Kagedal B, Pettersson A: Liquid-chromatographic determination of 5-S-L-cysteinyl-L-dopa with electrochemical detection in urine prepurified with a phenylboronate affinity gel. Clin Chem. 1983 Dec;29(12):2031-4. [PubMed:6416708 ]
- Dousa MK, Weinshilboum RM, Muenter MD, Offord KP, Decker PA, Tyce GM: L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients. J Neural Transm (Vienna). 2003 Aug;110(8):899-910. [PubMed:12898345 ]
- Di Stefano A, Mosciatti B, Cingolani GM, Giorgioni G, Ricciutelli M, Cacciatore I, Sozio P, Claudi F: Dimeric L-dopa derivatives as potential prodrugs. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1085-8. [PubMed:11327596 ]
- Tada K, Kudo T, Kishimoto Y: Effects of L-dopa or dopamine on human decidual prostaglandin synthesis. Acta Med Okayama. 1991 Oct;45(5):333-8. [PubMed:1755339 ]
- Crivellato E, Damiani D, Mallardi F: Comparison between the L-DOPA histofluorescence procedure and the indirect immunofluorescence with anti-T6 and -HLA-DR monoclonal antibodies in visualizing Langerhans cells of human epidermis. Acta Histochem. 1990;88(1):59-64. [PubMed:2113342 ]
- Michel H, Solere M, Granier P, Cauvet G, Bali JP, Pons F, Bellet-Hermann H: Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial. Gastroenterology. 1980 Aug;79(2):207-11. [PubMed:6995221 ]
- Streifler M, Avrami E, Rabey JM: L-dopa and the secretion of sebum in Parkinsonian patients. Eur Neurol. 1980;19(1):43-8. [PubMed:7371653 ]
- Hyland K, Clayton PT: Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10. [PubMed:1281049 ]
- Vassiliou AG, Vassilacopoulou D, Fragoulis EG: Purification of an endogenous inhibitor of L-Dopa decarboxylase activity from human serum. Neurochem Res. 2005 May;30(5):641-9. [PubMed:16176068 ]
- Chalimoniuk M, Stepien A: Influence of the therapy with pergolide mesylate plus L-DOPA and with L-DOPA alone on serum cGMP level in PD patients. Pol J Pharmacol. 2004 Sep-Oct;56(5):647-50. [PubMed:15591656 ]
- Blandini F, Nappi G, Fancellu R, Mangiagalli A, Samuele A, Riboldazzi G, Calandrella D, Pacchetti C, Bono G, Martignoni E: Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. J Neural Transm (Vienna). 2003 Aug;110(8):911-22. [PubMed:12898346 ]
- Shen H, Kannari K, Yamato H, Arai A, Matsunaga M: Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med. 2003 Mar;199(3):149-59. [PubMed:12703659 ]
- Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S: The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 2000 Oct 6;879(1-2):115-21. [PubMed:11011012 ]
- Pinho MJ, Serrao MP, Gomes P, Hopfer U, Jose PA, Soares-da-Silva P: Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells. Kidney Int. 2004 Jul;66(1):216-26. [PubMed:15200428 ]
|
---|